A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors

Clinical toxicities encountered with paclitaxel (Taxol).

Rowinsky Ek, Eisenhauer Ea, Arbuck Sg et al. · PubMed · 1993 · 698 citations

Pharmacy, Pharmacology, Toxicology +12

LAGRAN program for area and moments in pharmacokinetic analysis

Mario L. Rocci, William J. Jusko · Computer Programs in Biomedicine · 1983 · 415 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +8

Reversible encephalopathy and seizures as a result of conventional vincristine administration

Richard L. Hurwitz, Donald H. Mahoney, Dawna L. Armstrong et al. · Medical and Pediatric Oncology · 1988 · 78 citations

Medicine, Neurology, Oncology +14

Comparison of 1,2-dihydropyrido[3,4-b]pyrazines (1-deaza-7,8-dihydropteridines) with several other inhibitors of mitosis.

Bonnie J. Bowdon, William R. Waud, Glynn P. Wheeler et al. · PubMed · 1987 · 27 citations

Medicine, Medicinal Chemistry, Pharmacology +13

Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenyl-pyrido [3,4-b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate (NSC 370147) against selected tumor systems in culture and in mice.

Waud Wr, Leopold Wr, Elliott Wl et al. · PubMed · 1990 · 25 citations

Medicine, Oncology, Pharmacology +12